These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2565749)

  • 61. A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs.
    Ljungberg T; Ungerstedt U
    Pharmacol Biochem Behav; 1985 Sep; 23(3):479-85. PubMed ID: 2864704
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action.
    Cohen BM; Lipinski JF
    Life Sci; 1986 Dec; 39(26):2571-80. PubMed ID: 2879204
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Destruction of post-synaptic dopamine receptors prevents neuroleptic-induced activation of striatal tyrosine hydroxylase but not dopamine synthesis stimulation.
    Di Chiara G; Onali PL; Tissari AH; Porceddu ML; Morelli M; Gessa GL
    Life Sci; 1978 Aug; 23(7):691-6. PubMed ID: 29204
    [No Abstract]   [Full Text] [Related]  

  • 64. The D1 dopamine receptor antagonist SCH 23390 enhances REM sleep in the rat.
    Trampus M; Ongini E
    Neuropharmacology; 1990 Oct; 29(10):889-93. PubMed ID: 2147740
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The dopamine D1 receptor: biochemical and behavioral aspects.
    Andersen PH; Nielsen EB
    Adv Exp Med Biol; 1986; 204():73-91. PubMed ID: 2878580
    [No Abstract]   [Full Text] [Related]  

  • 66. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.
    Sayers AC; Bürki HR; Ruch W; Asper H
    Psychopharmacology (Berl); 1976 Dec; 51(1):15-22. PubMed ID: 13446
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of dopamine D-1 and D-2 antagonists on decision making by rats: no reversal of neuroleptic-induced attenuation by scopolamine.
    Ljungberg T; Enquist M
    J Neural Transm Gen Sect; 1990; 82(3):167-79. PubMed ID: 1979001
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intrastriatal infusions of ascorbate antagonize the behavioral response to amphetamine.
    White LK; Maurer M; Kraft ME; Oh C; Rebec GV
    Pharmacol Biochem Behav; 1990 Jul; 36(3):485-9. PubMed ID: 2377651
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The electrophysiology of dopamine (D2) receptors: a study of the actions of dopamine on corticostriatal transmission.
    Brown JR; Arbuthnott GW
    Neuroscience; 1983 Oct; 10(2):349-55. PubMed ID: 6138732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Unilateral neostriatal kainate, but not 6-OHDA, lesions block dopamine agonist-induced ascorbate release in the neostriatum of freely moving rats.
    Pierce RC; Miller DW; Reising DB; Rebec GV
    Brain Res; 1992 Nov; 597(1):138-43. PubMed ID: 1477726
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of antipsychotic drugs and their clinically inactive analogs on dopamine metabolism.
    Stanley M; Wilk S
    Eur J Pharmacol; 1977 Aug; 44(4):293-302. PubMed ID: 19267
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In vivo voltammetry with electrodes that discriminate between dopamine and ascorbate.
    Ewing AG; Wightman RM; Dayton MA
    Brain Res; 1982 Oct; 249(2):361-70. PubMed ID: 6814706
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of long-term haloperidol treatment on glutamate-evoked ascorbate release in rat striatum.
    Teagarden MA; Rebec GV
    Eur J Pharmacol; 2001 Apr; 418(3):213-6. PubMed ID: 11343692
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of prolactin responses to D-1 and D-2 antagonists in rats: Ro 22-1319 is a potent D-2 antagonist.
    Kaneda H; Shintani T; Kakigi T; Terada T; Tanimoto K
    Biol Psychiatry; 1989 Feb; 25(4):517-22. PubMed ID: 2564788
    [No Abstract]   [Full Text] [Related]  

  • 75. Buspirone: a potential atypical neuroleptic.
    Wood PL; Nair NP; Lal S; Etienne P
    Life Sci; 1983 Jul; 33(3):269-73. PubMed ID: 6135133
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reduction of the rewarding effect of brain stimulation by a blockade of dopamine D1 receptor with SCH 23390.
    Nakajima S; McKenzie GM
    Pharmacol Biochem Behav; 1986 Apr; 24(4):919-23. PubMed ID: 3520603
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390.
    Creese I; Chen A
    Eur J Pharmacol; 1985 Feb; 109(1):127-8. PubMed ID: 2859993
    [No Abstract]   [Full Text] [Related]  

  • 78. Behavioral activation in rats requires endogenous ascorbate release in striatum.
    Rebec GV; Wang Z
    J Neurosci; 2001 Jan; 21(2):668-75. PubMed ID: 11160445
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A dopaminergic mechanism mediates the d-amphetamine- and apomorphine-induced increase of ascorbic acid metabolism in the rat striatum.
    Miele M; Desole MS; Enrico P; Esposito G; De Natale G; Miele E
    Pharmacol Res; 1990; 22 Suppl 3():41-2. PubMed ID: 2097636
    [No Abstract]   [Full Text] [Related]  

  • 80. Ascorbate injury and EDTA (or manganese) protection of D2-dopamine receptors.
    Chan B; Seeman P; Davis A; Madras BK
    Eur J Pharmacol; 1982 Jun; 81(1):111-6. PubMed ID: 6126367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.